Here are five insights:
1. The company hopes to receive clearance to test its cell therapy drug in a clinical trial.
2. The therapy, BRTX-100, is intended to treat chronic lower back pain caused by degenerative disc disease.
3. BRTX-100 includes autologous cultured mesenchymal stem cells from a patient’s bone marrow.
4. The product is designed for a non-surgical, intradiscal procedure performed in a physician’s office.
More articles on spine:
Drs. Kern Singh, Hyun Bae & more: 5 spine surgeons & neurosurgeons recently receiving honors — Jan. 9, 2017
Are infections associated with analgesic steroid paste after spinal decompression? 5 key notes
3 spine surgeons in the headlines — Jan. 6, 2017
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
